Shandong Sanyuan Biotechnology Co 301206.SZ · CNY

Its shares trade on Shenzhen under the ticker 301206.SZ. It has been listed since 10 February 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥649.5m and net income of CN¥91.4m. At that date it held total assets of CN¥4.42bn and shareholders' equity of CN¥4.24bn.

Shandong Sanyuan Biotechnology Co., Ltd. engages in the research and development, manufacture, and sale of erythritol and new multi-functional sweeteners. The company is headquartered in Binzhou, Shandong. The company went IPO on 2022-02-10. The firm's main products are erythritol and compound sugar. The compound sugar products include momordica grosvenori compound sugar, stevia compound sugar, sucralose compound sugar and others. The firm's products are sold to America, Europe, Africa, Oceania and other regions.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Zaijian NieChairman of the Board, since 2012CN¥426,000
• Ms. Junling YuChief Financial OfficerCN¥153,200
• Mr. Baohua ChengGeneral Manager, Director, since 2012CN¥400,000
• Mr. Lupeng CuiAssistant General Manager, Director, since 2014CN¥300,300
• Mr. Hongfu WeiChief Engineer, Director, since 2012CN¥300,600
• Mr. Haijun ZhengAssistant General Manager, Director, since 2015CN¥298,100
• Mr. Yanlin DaiAssistant Chief EngineerCN¥152,500
• Mr. Liang GaoSecretary of the Board
• Mr. Lei NieDirector
• Mr. Haining TanIndependent Director
• Ms. Ling WangIndependent Director
• Mr. Gongsui YangIndependent DirectorCN¥16,700

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.